Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ADH1B | P00325 | 1/20 | 0.38 |
| ▸ | ADH1C | P00326 | 1/20 | 0.38 |
| ▸ | ADH1A | P07327 | 1/20 | 0.38 |
| ▸ | ADH7 | P40394 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11627153 | 0.98 | TSHR (0.42) | TSHRALDH1A1LTA4HLMNAGAA | |
| SCHEMBL28802206 | 0.76 | ALDH1A1 (0.44) | TSHRALDH1A1GAAKMT2AKDM4E | |
| SCHEMBL54705 | 0.76 | HSD17B10 (0.41) | LMNAKMT2ACYP2A6DRD2DRD4 | |
| SCHEMBL11421515 | 0.75 | LTA4H (0.39) | TSHRALDH1A1LTA4HLMNAGAA | |
| SCHEMBL21364389 | 0.72 | ST14 (0.45) | CA4CA1CA2CA9 | |
| SCHEMBL9747855 | 0.72 | TSHR (0.38) | TSHRALDH1A1LTA4HLMNAGAA | |
| SCHEMBL29013343 | 0.72 | CA1 (0.44) | TSHRALDH1A1LMNAKMT2ACA1 | |
| SCHEMBL9644264 | 0.71 | CA4 (0.39) | TSHRLTA4HCA4KCNA3 | |
| SCHEMBL29020559 | 0.70 | DRD4 (0.50) | TSHRALDH1A1GAAKMT2ADRD2 | |
| SCHEMBL11509363 | 0.70 | SRC (0.45) | TSHRLMNAKMT2ASRCKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 309 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119118939-A | Preparation method of 1, 2-benzisoxazole | 广东工业大学 | 2024-12-13 | — | — | CN | claimed |
| CN-117344131-A | Composite extraction system and extraction method for extracting lithium from lithium-containing brine | 浙江恒锂新能源有限公司 | 2024-01-05 | — | — | CN | claimed |
| CN-114585699-A | Self-stopping polishing composition and method | CMC材料股份有限公司 | 2022-06-03 | — | — | CN | claimed |
| CN-109851599-B | Preparation method of 2-aminobenzofuran compound | 青岛科技大学 | 2022-03-08 | — | — | CN | claimed |
| CN-108026412-A | Method and composition for processing dielectric substrate | 嘉柏微电子材料股份公司 | 2018-05-11 | — | — | CN | claimed |
| US-8557801-B2 | Compounds and compositions useful for the treatment of parasitic diseases | IRM LLC (BM) | 2013-10-15 | — | — | US | claimed |
| CN-102631977-A | Beneficiation method for ultrafine fraction cassiterite | GUANGZHOU RES INST NON FERROUS METALS | 2012-08-15 | — | — | CN | claimed |
| EP-2451814-A2 | FUSED IMIDAZOLES AND COMPOSITIONS COMPRISING THEM FOR THE TREATMENT OF PARASITIC DISEASES, SUCH AS E.G. MALARIA | IRM LLC (BM) | 2012-05-16 | — | — | EP | claimed |
| EP-1614418-B1 | use of(-)(3-trihalomethylphenoxy) (4-halophenyl)acetic acid derivatives for treatment of hyperuricaemia | METABOLEX INC (US) | 2011-09-14 | — | — | EP | claimed |
| US-20110059934-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2011-03-10 | — | — | US | claimed |
| CN-1636001-A | 2-amino-4-bicycloamino-6H-1, 3, 5-triazines, method for the production thereof and use thereof as herbicides and plant growth regulators | BAYER CROPSCIENCE GMBH (DE) | 2005-07-06 | — | — | CN | claimed |
| US-6737429-B2 | TREATMENT OF HIV MEDIATED DISEASES. | HOFFMANN-LA ROCHE INC. | 2004-05-18 | — | — | US | claimed |
| CN-1430599-A | Phenylglycine derivatives | HOFFMANN LA ROCHE (CH) | 2003-07-16 | — | — | CN | claimed |
| EP-1301481-A1 | PYRROLE DERIVATIVES FOR TREATING AIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-16 | — | — | EP | claimed |
| US-20020032221-A1 | Pyrrole derivatives | ROCHE PRODUCTS LIMITED (GB) | 2002-03-14 | — | — | US | claimed |
| WO-2002002524-A1 | PYRROLE DERIVATIVES FOR TREATING AIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-10 | — | — | WO | claimed |
| EP-0562512-B1 | Sulfonamidocarbonylpyridine-2-carboxamides and their use as medicines | HOECHST AG (DE) | 2001-02-21 | — | — | EP | claimed |
| EP-0705835-A1 | Quinoxalic-2,3-diones with an oxa or thiaheterocyclic fused ring | CIBA-GEIGY AG (CH) | 1996-04-10 | — | — | EP | claimed |
| US-5260446-A | Azo dye precursors | BASF AKTIENGESELLSCHAFT (DE) | 1993-11-09 | — | — | US | claimed |
| CN-88103601-A | N-PHENYLPYRAZOLE DERIVATIVES | — | 1988-12-28 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059934-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF PARASITIC DISEASES | SQLE, SGMS2, FDPS | TSHR 4657/4885ALDH1A1 1414/4885LTA4H 107/4885 |
| US-20020032221-A1 | Pyrrole derivatives | PYCR1, SARS1, MAVS | TSHR 4743/4885ALDH1A1 2902/4885LTA4H 2649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.